Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of January 2026. The document serves as a notice of an Extraordinary General Meeting of Shareholders scheduled for March 5, 2026, at the company's offices in Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance notice and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses on proposed corporate actions regarding equity compensation and capital structure.
Guidance, Outlook, and Corporate Actions
The Board of Directors has proposed four specific resolutions for shareholder approval at the upcoming meeting:
- Approval of Restricted Share Units (RSUs) for non-executive directors.
- Approval of RSUs for Dror Ben-Asher, Chief Executive Officer and Chairman.
- Approval of RSUs for Rick D. Scruggs, Chief Commercial Officer and Director.
- Approval of an increase in the Company's authorized share capital.
The record date for voting eligibility is January 23, 2026. The Board recommends a vote "FOR" all proposals. No specific financial guidance or risk factors are detailed in this notice.
Key Facts for Investor Verification
- Meeting Date: March 5, 2026, at 3:00 p.m. Israel time.
- Record Date: January 23, 2026 (holders of record on this date are entitled to vote).
- Proposed Actions: Grants of RSUs to key executives and directors, and an increase in authorized share capital.
- Position Statements: Shareholders may submit written statements by February 23, 2026.
- Financial Data: This filing contains no financial performance data; investors should refer to recent Form 20-F or quarterly reports for financial metrics.